James C Hamilton insider trades: Arrowhead Pharmaceuticals (ARWR) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where James reports to the SEC
Open-market buys and sales
16 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | ARWR | ↓ Sell | 10,000 | $64.19 | $642K | Direct | Mar 9, 2026 (4d) |
| Jan 5, 2026 | ARWR | ↓ Sell | 40,164 | $63.11 | $2.5M | Direct | Jan 5, 2026 (0d) |
| Oct 1, 2025 | ARWR | ↓ Sell | 20,000 | $35.00 | $700K | Direct | Oct 3, 2025 (2d) |
| Sep 12, 2025 | ARWR | ↓ Sell | 15,000 | $30.00 | $450K | Direct | Sep 16, 2025 (4d) |
| Sep 2, 2025 | ARWR | ↓ Sell | 15,000 | $25.00 | $375K | Direct | Sep 4, 2025 (2d) |
| Aug 15, 2025 | ARWR | ↓ Sell | 10,000 | $20.00 | $200K | Direct | Aug 15, 2025 (0d) |
| Jan 6, 2025 | ARWR | ↓ Sell | 32,729 | $19.82 | $649K | Direct | Jan 7, 2025 (1d) |
| Apr 1, 2024 | ARWR | ↓ Sell | 6,000 | $28.03 | $168K | Direct | Apr 3, 2024 (2d) |
| Jan 12, 2024 | ARWR | ↓ Sell | 7,940 | $36.89 | $293K | Direct | Jan 17, 2024 (5d) |
| Jan 5, 2024 | ARWR | ↓ Sell | 38,443 | $34.69 | $1.3M | Direct | Jan 5, 2024 (0d) |
| Jun 30, 2023 | ARWR | ↓ Sell | 3,000 | $35.53 | $107K | Direct | Jul 5, 2023 (5d) |
| Jan 5, 2023 | ARWR | ↓ Sell | 13,803 | $37.40 | $516K | Direct | Jan 6, 2023 (1d) |
| Jan 3, 2023 | ARWR | ↓ Sell | 10,338 | $38.38 | $397K | Direct | Jan 5, 2023 (2d) |
| Jan 5, 2022 | ARWR | ↓ Sell | 25,625 | $64.57 | $1.7M | Direct | Jan 6, 2022 (1d) |
| Jan 14, 2021 | ARWR | ↓ Sell | 10,000 | $81.29 | $813K | Direct | Jan 15, 2021 (1d) |
| Jan 6, 2021 | ARWR | ↓ Sell | 38,750 | $72.51 | $2.8M | Direct | Jan 7, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ARWR insiders
Open-market trades in the last 12 months
About James C Hamilton's insider trades
James C Hamilton is Chief Medical Officer at Arrowhead Pharmaceuticals (ARWR). Since Jan 6, 2021, James has reported no open-market purchases and 16 sales worth $13.6M on SEC Form 4. In the last 12 months: 2 sales ($3.2M).
Their filings also include grants and awards (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARWR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.